Coverage support available for AUSTEDO

Affordability through financial assistance programs

~90% of patients pay $10 or less per month
for AUSTEDO¹

AUSTEDO Copay Card: As little as $0 copay per month for eligible, commercially insured patients*
AUSTEDO Free Trial Voucher: Offer available for patients new to AUSTEDO (sampled patients are not eligible)*
Low-income subsidy (LIS): Medicare Part D patients who qualify for and utilize the LIS may pay as little as $9.85 per month for AUSTEDO²

Free Trial Vouchers and Copay Cards* available for patients starting on AUSTEDO at www.AUSTEDOcardform.com.

Comprehensive coverage helps make AUSTEDO more accessible

~87% of prescriptions are successfully processed and approved¹

Access for 90% of patients with insurance coverage (commercial, Medicare Part D, and Medicaid)¹
Available at both specialty and retail pharmacies

Request a visit from a Patient Support Specialist who can help with access and reimbursement, prescription pull-through, and patient assistance support^†

^†If you don’t have a Patient Support Specialist, reach out to your sales representative.

Prescription
coverage tool

Find health plans that cover AUSTEDO^® (deutetrabenazine) tablets in your state

Enter in a ZIP code or select a state, then select a plan type, select a plan, and click “Search.”

Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

Commercial
DME MAC
EGWP
Employer
Fed Prog
FEHBP
HIX
IDN/HOSP
MAC A
MAC B
Managed Medicaid
Medicare MA
Medicare PDP
Medicare SN
Medi-Medi
Municipal Plan
PACE
PBM
Pvt HIX
State Medicaid
Union

NA, not available.
Please note that plans may have multiple formularies and they are subject to change by the plan. Please check with the health plan directly to confirm formulary status, requirements, and coverage information for individual patients.
Source: Fingertip Formulary database as of 03/2023.
This information is intended only to show the formulary coverage status for each product and should not be construed to make any comparisons of safety, efficacy or other clinical outcome.

VIEW RESOURCES FOR YOU & YOUR PATIENTS

*See Terms and Conditions on www.AUSTEDOcardform.com.

REFERENCES: 1. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 2. Medicare. Find your level of Extra Help (Part D). Accessed June 10, 2022. https://www.medicare.gov/your-medicare-costs/get-help-paying-costs/find-your-level-of-extra-help-part-d

Important safety information

Depression and Suicidality in Patients with Huntington’s Disease: AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO is contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Contraindications: AUSTEDO is contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO is also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine (Xenazine^®) or valbenazine (Ingrezza^®).

Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

QTc Prolongation: AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO is administered within the recommended dosage range. AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

Akathisia, Agitation, and Restlessness: AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Parkinsonism: AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO.

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington’s disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.

Please see full Prescribing Information, including Boxed Warning.

The brands listed are registered trademarks of their respective owners.

Coverage support available for AUSTEDO

Affordability through financial assistance programs

Comprehensive coverage helps make AUSTEDO more accessible

Prescription coverage tool

Find health plans that cover AUSTEDO® (deutetrabenazine) tablets in your state

Find health plans that cover AUSTEDO® (deutetrabenazine) tablets in your state

Prescription
coverage tool

Find health plans that cover AUSTEDO^® (deutetrabenazine) tablets in your state

Find health plans that cover AUSTEDO^® (deutetrabenazine) tablets in your state